Abbott’s forecast for 2026 projects a slight decrease in adjusted EPS due to the impact of the Exact Sciences acquisition, while also highlighting significant revenue growth contributions from the acquisition.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What is the expected impact of the Exact Sciences acquisition on Abbott's profit forecast for 2026?
Abbott’s management explicitly quantified how the Exact Sciences acquisition affects its 2026 adjusted earnings per share (EPS) guidance, which is the closest filed/provided proxy in the excerpt for the “profit forecast.”
Implication: On Abbott’s own forecast metric (adjusted EPS), the acquisition is expected to be slightly accretive/neutral on an earnings basis only after financing/other effects are considered, but the stated near-term impact is dilution of $0.20 at the forecast midpoint. 1
Implication for “profit forecast”: The comparable-sales adjustment is primarily a growth-reporting and modeling normalization, but it frames why Abbott is able to update guidance while explicitly separating the acquisition’s dilution effect (profit impact) from the sales-growth comparability effect. 1
While the excerpt does not provide a full 2026 segment-by-segment profit bridge, it does provide context that Abbott expects Exact Sciences to contribute to earnings power via sales expansion:
Implication: Even though the acquisition creates near-term adjusted EPS dilution of $0.20 at the midpoint, Abbott is concurrently forecasting material incremental 2026 revenue (about $3B) from Exact Sciences, supporting the notion that the longer-run earnings impact should be more favorable than the initial dilution suggests. 123
Abbott’s 2026 profit forecast (as represented by adjusted EPS) is expected to be lower at the midpoint by $0.20 due to dilution from the Exact Sciences acquisition, moving the midpoint from $5.68 to $5.48. 1
At the same time, Abbott forecasts Exact Sciences will contribute about $3 billion of incremental 2026 sales and supports that the business is integrating well, which is intended to bolster longer-term earnings capacity even as the forecast reflects upfront dilution. 23
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
This discussion details how Abbott's recent acquisition of Exact Sciences influences its 2026 profit forecasts, highlighting guidance adjustments and dilution effects.
Sources used
Research questionWhat is the expected impact of the Exact Sciences acquisition on Abbott's profit forecast for 2026?
Answer outline
This analysis examines how the acquisition of Exact Sciences influences Abbott’s Q1 2026 sales figures and growth projections, highlighting the integration effects and future contributions.
Sources used
Research questionHow is the acquisition of Exact Sciences expected to impact Abbott's sales and growth in Q1 2026?
Answer outline
This analysis examines how Abbott's acquisition of Exact Sciences influences its 2026 profit forecast and sales outlook, highlighting key guidance adjustments and dilution effects.
Sources used
Research questionWhat is the expected impact of the Exact Sciences acquisition on Abbott's profit forecast for 2026?
Answer outline
Abbott reports that Nutrition momentum is improving and tracking slightly ahead of expectations, driven by pricing actions, new product launches, and stronger commercial execution. Management highlights a Q2 uptick to mid-single-digit growth, supported by international pediatric and adult nutrition momentum, and outlines upcoming launches—collagen protein shake, adult protein-HMB-creatine line, and a new infant formula—as catalysts for acceleration in the second half, while keeping guidance unchanged.
Sources used
Research questionWhat did management say about Nutrition momentum and product launches?
Answer outline
This analysis explores how Abbott's recent acquisition of Exact Sciences influences its Q1 2026 sales and growth prospects, highlighting key financial impacts and strategic considerations.
Sources used
Research questionHow is the acquisition of Exact Sciences expected to impact Abbott's sales and growth in Q1 2026?
Answer outline
This analysis details the anticipated impact of the Exact Sciences acquisition on Abbott’s 2026 profit forecast, highlighting dilution effects and long-term growth strategies.
Sources used
Research questionWhat is the expected impact of the Exact Sciences acquisition on Abbott's profit forecast for 2026?
Answer outline
This analysis explores how Abbott's recent acquisition of Exact Sciences impacts its Q1 2026 sales, growth metrics, and future outlook, highlighting the strategic significance of the deal.
Sources used
Research questionHow is the acquisition of Exact Sciences expected to impact Abbott's sales and growth in Q1 2026?
Answer outline
This discussion analyzes how Abbott's acquisition of Exact Sciences influences its Q1 2026 sales figures and long-term growth outlook, with focus on reported growth rates and future guidance.
Sources used
Research questionHow is the acquisition of Exact Sciences expected to impact Abbott's sales and growth in Q1 2026?
Answer outline
Abbott's Q2 2026 diagnostics momentum remains robust and broad-based, with hospital-lab testing driving faster growth than core labs. Management positions diagnostics as a real-time barometer of healthcare activity and signals resilience in US procedure volumes through the second half of 2026, even in ACA disenrollment states. The findings imply sustained hospital-driven demand and a durable outlook for US healthcare procedures.
Sources used
Research questionHow do Abbott’s diagnostic test volume trends and the split between US core lab and hospital labs inform your outlook for US healthcare procedure volumes in the second half of 2026?
Answer outline
Abbott outlines a reimbursement-driven rest-of-year outlook for Libre CGM, suggesting US Type 2 non-insulin coverage could unlock growth in the fall and likely accelerate sales when it arrives. The dual-key glucose sensor is in late-stage discussions, but timing remains uncertain. Absent reimbursement expansion, growth may plateau around 8-9% until catalyst arrives, making timing critical for near-term acceleration.
Sources used
Research questionWhat is the outlook for Libre CGM growth for the rest of the year, including the US timing for the dual-key glucose sensor and type 2 non-insulin coverage, and could these developments accelerate CGM growth or maintain the current rate?
Answer outline
🚀 Abbott is aggressively enhancing CGM adoption in the US basal diabetes segment by expanding sales coverage, integrating CGM data into Epic, and launching innovative sensors. The company targets overcoming key barriers like clinician experience and time constraints to unlock substantial market growth opportunities. 📈
Sources used
Research questionHow does Abbott plan to accelerate CGM adoption in the US basal diabetes segment beyond current efforts, and what are the key barriers?
Answer outline
Cencora reports approximately 7% core growth in Q2 2026, suggesting underlying performance remains within its long-term framework despite WAC/IRA headwinds and customer losses. Management trimmed fiscal 2026 revenue guidance to 4-6%, but maintains a resilient long-term operating-income outlook supported by margin gains from mail-order conversions and ongoing OneOncology integration.
Sources used
Research questionWhat is the impact on long-term revenue and operating income growth from WAC/IRA adjustments, the loss of the oncology and grocery customers, and faster brand conversions at the large mail-order customer, given the reported core growth near 7%?
Answer outline
Dafinchi